Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportNeurosciences

NR2B

Lisheng Cai, Jeih-San Liow, Cheryl Morse, Riley Davies, Lester Manly, Sami Zoghbi, Robert Innis and Victor Pike
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 83;
Lisheng Cai
1National Institute of Mental Health Bethesda MD United States
6National Institute of Mental Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeih-San Liow
2Molecular Imaging Branch National Institute of Mental Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl Morse
3NIH Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Riley Davies
1National Institute of Mental Health Bethesda MD United States
6National Institute of Mental Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lester Manly
1National Institute of Mental Health Bethesda MD United States
6National Institute of Mental Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sami Zoghbi
4NIMH Great Falls VA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Innis
5National Institute Mental Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor Pike
1National Institute of Mental Health Bethesda MD United States
6National Institute of Mental Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

83

Objectives: NR2B is the most studied NMDA receptor subunit within the NMDA receptor complex and its expression is largely limited to forebrain regions and dorsal horn of the spinal cord [1]. NR2B is considered to be a therapeutic target for schizophrenia, stroke, and neurodegenerative diseases, especially neuro-pain. Therapeutics targeting NR2B rather than the NMDA channel may have fewer side-effects [1]. The quantification of NR2B subunits could help to elucidate the involvement of this subunit and the NMDA receptor in neuropsychiatric disorders and also assist in drug development [2]. Previously, we have reported 4 PET radioligands for the NR2B subunit within NMDA receptors, namely (R) and (S) forms of [11C]NR2B-SMe and [11C]NR2B-Me [3]. The NIMH Psychoactive Drug Screening Program (PDSP) evaluated the 4 PET radioligands against the common 120 or so protein targets in brain, and found intereference from σ1, σ2, and hERG at different levels. Because sigma receptors (σ1, σ2) are physically intertwined with NMDA receptors [4], the possible influence of these receptors on PET imaging of NR2B with the mentioned radioligands was a concern. Here we aimed to assess whether NR2B-SMe had potent interaction with σ1 receptors in rat brain by challenging the PET σ1 receptor specific signal obtained in rats with the known selective radioligand, [18F]FTC146 [5]. Methods: PET imaging of brain was performed after intravenous administration of [18F]FTC146 to rats at baseline and after administration with NR2B-selective ligands, such as NR2B-SMe and Ro 25 6981, or σ1 receptor-selective ligands, such as FTC146, and BD1047 (each at 0.01−3 mg/kg, i.v. at 10 min before radioligand injection).

Results: The precursor of [18F]FTC146 was synthesized as reported [5]. The radiolabeling method was modified from its original report, and the radioligand was obtained in 4−6% yields from cyclotron-produced [18F]F- and with a radiochemical purity of >98% and a mean molar activity of 76 GBq/μmol. PET imaging of [18F]FTC146 in rats at baseline showed moderately high brain radioactivity uptakes, reaching 4-5 SUV at 5 min (Figure). Pre-blocking with self, BD1047, a NR2B-selective ligand, either Ro 25 6981 or NR2B-SMe, were similarly effective (up to 95%) (Figure), but with markedly different ED50 values of 46 nmol/kg for FTC146, 169 nmol/kg for BD1047, and 1064 nmol/kg for NR2B-SMe. (Figure. The whole brain PET time activity curves in rats at baseline, preblocking using different dose of FTC146, and dose-response curves for NR2B-SMe, FTC146, and BD1047.)

Conclusions: The σ1 receptor-selective radioligand [18F]FTC146 was used in PET imaging of rat brain. It showed high brain uptake, which could be pre-blocked by self, a σ1 receptor ligand BD1047, and a NR2B-selective ligand NR2B-SMe, but at markedly different ED50 values. The ED50 for avidly brain-penetrant NR2B-SMe gave by far the highest value, implying only weak interaction with σ1 receptors. Influence of σ1 receptors on the PET imaging of NR2B receptors with [11C]NR2B-SMe is therefore likely negligible. Research Support: Intramural Research Program of the National Insitutes of Health (NIMH). References: [1] Zhuo M, Neuropharmacology, 2017, 112, 228. [2] Kassenbrock A, et al., Curr. Top. Med. Chem. 2016; 16, 1830. [3] Cai L et al., J. Nucl. Med. 2020, In press. [4] Pabba M and Sibille E. Mol. Neuropsychiatry, 2015, 1, 47. [5] James ML et al., J. Med. Chem. 2012, 55, 8272.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 61, Issue supplement 1
May 1, 2020
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
NR2B
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
NR2B
Lisheng Cai, Jeih-San Liow, Cheryl Morse, Riley Davies, Lester Manly, Sami Zoghbi, Robert Innis, Victor Pike
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 83;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
NR2B
Lisheng Cai, Jeih-San Liow, Cheryl Morse, Riley Davies, Lester Manly, Sami Zoghbi, Robert Innis, Victor Pike
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 83;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Neurosciences

  • PET CT Quantification to direct Alzheimer’s patients to anti-amyloid therapy
  • Multicenter trial study for usefulness of physical parameters toward the standardization of brain SPECT image: relation to visual analysis
  • Assessment of Brain Perfusion 123I-IMP SPECT imaging Using Low Energy High Resolution Collimator image reconstructed by Flash 3D
Show more Neurosciences

Basic Science - Synaptic activity and other mechanisms

  • Single-cell analysis reveals the key role of enhanced endothelial glucose uptake in neurometabolic coupling
  • Longitudinal Brain FDG PET Profiles Displaying Neuron Secondary Degeneration in the Visual Pathway in An Optic Nerve Crush(ONC) Rat Model
Show more Basic Science - Synaptic activity and other mechanisms

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire